NCT01513135View on ClinicalTrials.gov

A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions
HIV Infections
Interventions
BIOLOGICAL

Tat

Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin

BIOLOGICAL

Placebo

Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin

Trial Locations (1)

0204

Medunsa Clinical Research Unit (MeCRU), Medunsa

All Listed Sponsors
collaborator

Italian Ministry of Foreign Affairs - General Direction for Cooperation and Development

UNKNOWN

lead

Barbara Ensoli, MD

OTHER

NCT01513135 - A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers | Biotech Hunter | Biotech Hunter